Navigation Links
Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment
Date:10/28/2008

Kainos to Fund Up to $25 Million to Advance P-552

DURHAM, N.C., Oct. 28 /PRNewswire/ -- Parion Sciences, Inc. and Kainos Medicines, Inc. today announced that they have entered into an agreement to co-develop Parion's proprietary epithelial sodium channel blocker, P-552, for the treatment of dry mouth associated with primary Sjogren's syndrome.

Under the agreement, the companies will collaborate in the clinical development of P-552. Kainos will provide funding to help advance the program through the end of Phase II clinical testing, supplying up to $25 million upon completion of all milestones. Parion will be responsible for the oversight of the clinical development program while Kainos will provide CMC (chemistry, manufacturing and controls) expertise. Upon the successful completion of the Phase II program, Parion and Kainos will determine the Phase III clinical development and commercialization of P-552.

In a Phase I/II clinical study completed in April 2008, P-552 was found to be safe and tolerable in subjects with primary Sjogren's disease. The study demonstrated promising results in several key quality of life parameters including mouth dryness, mouth comfort and ability to sleep, as assessed by Visual Analogue Scale (VAS).

"Sjogren's syndrome patients are seeking effective relief of their dry mouth. By combining the talents and expertise of two proven development teams, we believe we can accelerate the clinical development of P-552 to effectively address this unmet need," said M. Ross Johnson, Parion Chief Executive Officer. "This partnership represents the second application of our portfolio of sodium channel blockers as we continue to expand Parion's unique technology and novel compound library into other diseases requiring mucosal hydration."

"I am very pleased that Kainos and Parion will be working together on the development of P-552," said M.C. Kang, Kainos Chief Executive Officer. "Strategically, each pa
'/>"/>

SOURCE Parion Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
2. Human Pheromone Sciences, Inc. - Shareholder Update
3. Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
4. Isis Ibis Biosciences Subsidiary Highlights the Power of the Ibis T5000 Pathogen Identification and Characterization System at the ICAAC/IDSA Meeting
5. Caliper Life Sciences Third Quarter 2008 Financial Results Conference Call Notice
6. Advanced Life Sciences Completes Debt Transaction
7. LI-COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging
8. MedTechIQ Selects TheBrain to Visualize Expansive Biointellingence Database and Connect the Dots Between Life Sciences, Medicine and Venture Capital
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
10. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
11. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 AbilTo, Inc., the nation,s leading ... submission has been accepted as a presentation to be ... taking place on June 5-6, 2015 in Boston, ... American Diabetes Association, the cost of diabetes to the ... a result of increased inpatient, outpatient, and pharmacy costs, ...
(Date:4/21/2015)... DIEGO , April 21, 2015 ... design and development, custom automation, and contract manufacturing, ... and accessible flow cytometry and cell sorting technology ... to develop a novel flow cytometry platform. ... , NanoCellect Biomedical has developed a microchip-based cell ...
(Date:4/21/2015)... NEW YORK , April 21, 2015 ... announced that its Board of Directors has elected ... of the Transaction and Pricing Committee, with oversight on ... a member of the Audit Committee, the Compensation Committee ... Upon his election, Mr. Azria commented: "I have a ...
(Date:4/21/2015)... , April 21, 2015  Tute Genomics, a leading provider ... Josh Forsythe as VP of Marketing. Mr. Forsythe ... a significant expansion in its commercial operations over the last ... " Josh Forsythe is a tremendous addition to ... MBA, CEO of Tute Genomics. "Josh,s vast experience commercializing software ...
Breaking Biology Technology:AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 2Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 4Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4
... Phase 1 clinical studies support advancement to Phase 2 ... Roche polymerase inhibitors -, BRISBANE, Calif., Sept. 24 ... four abstracts from clinical and,in-vitro studies of ITMN-191 (R7227) ... American Association for the Study of Liver Diseases,(AASLD, Oct. ...
... new screening platform for antibody therapeutics, BASEL, ... today that it has completed the acquisition of ... of ARIUS Research (TSX: ARI). On,September 19th, the ... previously approved by the security holders and announced ...
... signing to follow his presentation, WASHINGTON, Sept. ... global marketplace, and the role of,financing are focus ... presentations will focus on the convergence of the,MedTech ... patient monitoring,technologies, critical issues to consider when entering ...
Cached Biology Technology:InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 2InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 3InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 4InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 5InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 6Roche completes acquisition of ARIUS 2Former Speaker of the House Newt Gingrich Featured Wednesday 2
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
(Date:3/26/2015)... , March 26, 2015 The ... social, recreation and athletic club, today announced it has ... allow freedom of movement for members and staff, while ... a comprehensive process, we selected FST,s IMID Access system ... convenience for our members and staff, in addition to ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... upcoming paper from Dr. David Wassarman (University of Wisconsin ... 1 issue of G&D lends new insight into the ... (A-T) is a rare, genetic immunodeficiency disease that affects ... cancer predisposition. A-T is caused by recessive mutations in ...
... to designing something, its hard to find a better ... principle, a diverse, interdisciplinary group of researchers at the ... to synthesize magnetic nanoparticles that could be used for ... high-density memory devices, or as magnetic seals in motors. ...
... nature vs. nurture debate is familiar to most people, ... two. A new paper published this week in the ... similar balance between the genes we inherit—nature—and the environment—nurture—in ... the age of personal genomics, in which each of ...
Cached Biology News:Researchers mimic bacteria to produce magnetic nanoparticles 2Researchers mimic bacteria to produce magnetic nanoparticles 3
X-Gal (5-Bromo-4-Chloro-3-Indoyl-beta -D-Galactopyranoside)...
...
Recalibration of HL-2000-CAL products...
Mature rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and processed within 45 minutes. It is then filtered through gauze, pooled in an ...
Biology Products: